Date: 05.02.2021

To

The Manager
Department of Corporate Service
BSE Limited
PJ Towers, Dalal Street,
Fort Mumbai-400001.

BSE Script Code: 524572

Subject: Outcome of Board Meeting - February 05, 2021

Ref.: Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Dear Sir / Madam,

We inform you that the Board of Directors of the Company, at their meeting held today i.e. Friday, February 05, 2021 has approved the unaudited financial results for the quarter and nine months ended 31 December 2020.

Pursuant to above referred regulations, we enclose the following documents:

- a) Statement of Financial Results for the Quarter and Nine Months ended 31st December, 2020.
- b) Limited Review Reports issued by M/s. PPKG & Co, the Statutory Auditors of the Company.

The meeting of the Board of Directors of the Company Commenced at 2.30 PM and concluded at 5.15 PM.

The financial results are also available on the website of the Company at www.pharmaids.com and also on the website of BSE Ltd. Viz. www.bseindia.com.

You are requested to take the above information on record.

Thanking You,

Yours faithfully

For Pharmaids Pharmaceuticals Limited

S. Padmaja Kalyani

Director (DIN: 03096445)

HYD-95

CIN No: L52520TG1989LC009679, GSTIN No: 36AABCP4657N2ZW Email: pharmaids125@gmail.com, Web: www.pharmaids.com



Pharmaids Pharmaceuticals Limited

Pharmaids Pharmaceuticals Limited

Statement of Unaudited Profit and Loss account for the Third Quarter and Nine Months Period ended 31st December, 2020

Rs. (In Lakhs)

			Quarter Ended		Nine Months Period Ended		Year ended
	22 - 10 - 100	U	naudited (Reviewe	ed)	Unaudited (Reviewed)		Audited
	Particulars Particulars	December 31,	September 30,	December 31,	December 31,	December 31,	March 31, 2020
		2020	2020	2019	2020	2019	
1	Revenue	341.00	325.58	-	666.58	-	0.00
2	Other Income		•	-	2.63		0.00
3	Total Income	341.00	325.58		669.22	-	-
4	Expenses						
	a) Cost of Materal Consumed					-	0.00
	b) Purchase of Stock in Trade	391.69	382.61	-	774.30	-	0.00
	c) Changes in Inventories of Stock-in-Trade, Work in						
	Progress and Finished Goods	(57.35)	(70.29)		(127.64)	-	0.00
	d) Employee Benefit Expenses	1.18	0.60	0.31	2.07	1.82	2.28
	e) Finance Cost	•		-	-	0.08	0.08
	f) Depreciation and Amortisation Expenses	1.13	1.11	0.93	3.36	2.79	3.88
	g) Other Expenses	2.44	6.70	18.06	10.02	29.22	31.27
	Total Expenses	339.09	320.72	19.30	662.10	33.91	37.52
5	Profit/(loss) before Exceptional items and Tax	1.91	4.86	(19.30)	7.11	(33.91)	(37.52)
6	Exceptional Items	-	14:		-		-
7	Profit/(loss) before tax	1.91	4.86	(19.30)	7.11	(33.91)	(37.52)
8	Tax expense:						
	(1) Current tax	0.95	1.13		2.08	-	0.00
Г	(2) Deferred tax	-	-			-	(40.87)
9	Profit (Loss) for the period from continuing operations	0.97	3.73	(19.30)	5.03	(33.91)	3.35
10	Profit/(loss) from discontinued operations	-	-	-		9	•
11		-		-			-
12	Profit/(loss) from Discontinued operations (after tax)	-	-			-	-
	Profit/(loss) for the period	0.97	3.73	(19.30)	5.03	(33.91)	3.35
	Other Comprehensive Income						
-							
ı	A (i) Items that will not be reclassified to profit or loss	-		-	-	-	
Н	(ii) Income tax relating to items that will not be						
ı	reclassified to profit or loss	-		-	-		
Г	B (i) Items that will be reclassified to profit or loss	-	-		-		-
Г	(ii) Income tax relating to items that will be reclassified						
ı	to profit or loss		-	-			
Г	Total Comprehensive Income for the period (Comprising			1			
	Profit (Loss) and Other Comprehensive Income for the		1	I	1	1	
15	period)	-		-	-	-	-
16	Earnings per equity share (for continuing operation):	0.97	3.73	(19.30)	5.03	(33.91)	
H	(1) Basic	0.01	0.04	(0.19)	0.05		
H	(2) Diluted	0.01	0.04	(0.19)	0.05	(0.33)	0.03

NOTES: 1. The above results were approved at the meeting of the Board of Directors held on February 05,2021. 2. The Company operates in a single segment 3. As required under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation,2015, the Limited Review by the Statutory Auditors has been completed and the Unmodified Report forwarded to BSE Ltd. The said Report does not have any impact on the above results and Notes which needs explanation. 4. As per NCLT order dated 27-09-2019, Pharmaids Pharmaceuticals Limited undergone amalgamation with Emergent Bio Naturals Limited w.e.f 01-04-2018 as explained in Para 5 of the Auditor's Report. 5. The previou's quarter's / year's figures have been regrouped / rearranged whereever necessary to make it comparable with the current quarter / period. 6. During this pandemic business operations and financial position has revealed that there has been no significant impact on company's financial results as at 31st December, 2020. However the impact assessment of COVID-19 will be a continuing process given the uncertainties associated with its nature and duration and accordingly the impact may be different from that estimated as at the date of approval of these financial results. The Company will continue to monitor such impact to future economic conditions.

Place: Hyderabad Date: 05/02/2021 Valuad

S.Padmaja Kalvani

Office Address: 503, Amrutha Estate, Himayath Nagar, Hyderabad - 500029. Ph: 040 - 40122151

CIN No: L52520TG1989LC009679, GSTIN No: 36AABCP4657N2ZW Email: pharmaids125@gmail.com, Web: www.pharmaids.com



Pharmaids Pharmaceuticals Limited

<u>Pharmaids Pharmaceuticals Limited</u> Balance Sheet as at 31st December, 2020

Rs. (In Lakhs)

Particulars No. 31.12.2020 31.03.2020			Note	Figures as at the and of	Figures as at the and of
1 ASSETS Non-current assets (a) Property, Plant and Equipment (b) Capital work-in-progress (c) Investment Property (d) Goodwill (e) Other Intangible assets (f) Intangible assets under development (g) Biological Assets other than bearer plants (h) Financial Assets (ii) Investments (iii) Trade receivables (iiii) Loans (iv) Others (to be specified) (j) Other non-current assets (i) Other non-current assets (ii) Investments (ii) Trade receivables (iii) Loans (iv) Others (to be specified) (j) Deferred tax assets (iii) Investments (iii) Trade receivables (iii) Investments (iii) Trade receivables (iv) Investments (iv) San And Cash equivalents (iv) San Abalances other than (iii) above (v) Loans (vi) Others (to be specified) (c) Current Tax Assets (Net) (d) Other current assets FOULTY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity (a) Equity Share capital (b) Other Equity (c) Equity Share capital (d) Deformonical liabilities (i) Borrowings (iii) Trade payables (iiii) Other financial liabilities (c) Current ilabilities (d) Other non-current liabilities (a) Financial Liabilities (i) Derrowings (iii) Trade payables		Particulars Particulars	1-5000	NATION AND ADDRESS OF THE PARTY	1553
ASSETS Non-current assets (a) Property, Plant and Equipment (b) Capital work-im-progress 45.00 (c) Investment Property - (d) Goodwill - (e) Other Intangible assets (f) Intangible assets (f) Intangible assets under development (g) Biological Assets under development (g) Biological Assets sother than bearer plants (h) Financial Assets (l) Investments (li) Investments (li) Investments (lii) Capital Capit					
Non-current assets	1			3	4
(a) Property, Plant and Equipment (b) Capital work-in-progress (c) Investment Property (d) Goodwill (e) Other Intangible assets (f) Intangible assets under development (g) Biological Assets under development (g) Biological Assets under development (f) Intancial Assets (f) Intangible assets (f) Investments (f) Trade receivables (f) Investments (f) Others (to be specified) (f) Others (to be specified) (f) Other non-current assets (g) Investments (g) Investments (g) Trade receivables (g) Investments (g) Trade receivables (g) Investments (g) Investments (g) Investments (g) Investments (g) Trade receivables (g) Other current assets Total Assets Total Assets EQUITY AND LIABILITIES Equity (g) Equity Share capital (g) Other current liabilities (g) Financial Liabilities (g) Finan	1	W. C.			
(b) Capital work-in-progress (c) Investment Property (c) Goodwill (e) Other Intangible assets (f) Intangible assets under development (g) Biological Assets other than bearer plants (h) Financial Assets (i) Investments (ii) Trade receivables (iii) Trade receivables (iv) Others (to be specified) (i) Other non-current assets (c) Inventories (d) Financial Assets (i) Investments (e) Financial Assets (i) Investments (ii) Trade receivables (iii) Trade receivables (iv) Others (to be specified) (iv) Other non-current assets (c) Inventories (d) Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash equivalents (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans (vi) Others (to be specified) (c) Current Tax Assets (Net) (d) Other current assets EQUITY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity UABILITIES Non-current liabilities (c) Financial Liabilities (d) Deferred tax liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (d) Other courrent liabilities (ii) Borrowings (iii) Trade payables (iii) Irrade payables				F 10	8.31
(c) Investment Property (d) Goodwill (e) Other Intangible assets (f) Intangible assets under development (g) Biological Assets other than bearer plants (h) Financial Assets (ii) Investments (iii) Trade receivables (iii) Loans (iv) Others (to be specified) (i) Otherred tax assets (net) (j) Other non-current assets 2 Current assets (a) Investments (ii) Irrade receivables (b) Financial Assets (i) Investments (ii) Irrade receivables (b) Financial Assets (ii) Investments (iii) Cash and cash equivalents (iii) Cash and cash equivalents (iv) Others (to be specified) (c) Current Tax Assets (Net) (d) Others (to be specified) (c) Current Tax Assets (Net) (d) Other current assets EQUITY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity LIABILITIES 1 Non-current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables (c) Current liabilities (d) Other financial liabilities (d) Other financial liabilities (d) Other non-current liabilities (d) Other non-current liabilities (d) Other non-current liabilities (d) Fronoisions (c) Deferred tax liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (other than those specified in item (d) Other non-current liabilities (d) Trade payables (iii) Trade payables (iii) Trade payables (iii) Trade payables					100 miles
(d) Goodwill (e) Other Intangible assets (f) Intangible assets under development (g) Biological Assets other than bearer plants (h) Financial Assets (i) Investments (ii) Trade receivables (iii) Loans (iv) Others (to be specified) (i) Other non-current assets (i) Investments (i) Investments (i) Investments (i) Investments (i) Investments (i) Investments (ii) Trade receivables (iii) Investments (iii) Trade receivables (iiii) Cash and cash equivalents (iv) Bank balances other than (iiii) above (v) Loans (vi) Others (to be specified) (c) Current Tax Assets (Net) (d) Other current assets EQUITY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity (c) Equity Share capital (d) Other current liabilities (i) Borrowings (iii) Trade payables (iiii) Other financial liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (i) Borrowings (ii) Trade payables (iii) Other financial liabilities (i) Borrowings (ii) Trade payables (iii) Other financial liabilities (i) Borrowings (ii) Trade payables (iii) Other financial liabilities (i) Borrowings (ii) Trade payables (iii) Other financial liabilities (i) Borrowings (ii) Trade payables (iii) Other financial liabilities (iii) Other financial liabilities (iii) Other fonn-current liabilities (iii) Other financial liabilities (iii) Other fonn-current liabilities (iiii) Other fonn-current liabilities (iiii) Other fonn-current liabilities (iiii) Other fonn-curr				45.00	45.00
(e) Other Intangible assets (f) Intangible assets under development (d) Biological Assets tother than bearer plants (h) Financial Assets (i) Investments (ii) Trade receivables (iii) Loans (iv) Others (to be specified) (i) Deferred tax assets (net) (j) Other non-current assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans				-	-
(f) Intangible assets under development - (g) Biological Assets other than bearer plants - (h) Financial Assets - (ii) Investments - (ii) Chans 632.43 (iii) Chans 632.43 (iv) Others (to be specified) 34.58 (j) Other non-current assets - 2 Current assets 127.64 (a) Inventories 127.64 (b) Financial Assets - (j) Investments - (ii) Investments 93.71 (iii) Cash and cash equivalents 7.47 (iv) Bank balances other than (iii) above - (v) Loans 36.55 (v) Others (to be specified) - (c) Current Tax Assets (Net) - (d) Other current assets 10.75.04 8 8 EQUITY AND LIABILITIES Equity 1,026.88 1,075.04 (a) Equity Share capital 1,026.88 1,075.04 (a) Equity Share capital 1,026.88 1,026.88 (b) Other Equity (a) Financial Liabilities (a) Financial Liabilities (i) Deferred tax liabilities (o				-	-
(g) Biological Assets other than bearer plants (h) Financial Assets (i) Investments (ii) Trade receivables (iii) Loans (iv) Others (to be specified) (i) Deferred tax assets (net) (j) Other non-current assets 2 Current assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans (vi) Others (to be specified) (c) Current Tax Assets (Net) (d) Other current assets EQUITY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity LIABILITIES 1 Non-current liabilities (i) Borrowings (iii) Trade payables (iii) Other financial liabilities (c) Deferred tax liabilities (d) Other non-current liabilities (e) Financial Liabilities (f) Borrowings (c) Current Tax Assets (f) Trade payables (ii) Other non-current liabilities (i) Borrowings (c) Deferred tax liabilities (d) Other non-current liabilities (e) Financial Liabilities (f) Borrowings (g) Trade payables (g) Financial Liabilities (g) Financi				-	
(if) Financial Assets (i) Investments (ii) Trade receivables (iii) Loans (iv) Others (to be specified) (i) Deferred tax assets (net) (j) Other non-current assets 2 Current assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans (v) Loans (v) Others (to be specified) (c) Current Tax Assets (Net) (d) Other current assets EQUITY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity (a) Equity Share capital (b) Other Equity (a) Equity Share capital (c) Current flash is in the specified in item (b) Provisions (c) Deferred tax liabilities (ii) Borrowings (ii) Trade payables (iii) Other non-current liabilities (c) Perorwings (d) Financial Liabilities (e) Provisions (c) Deferred tax liabilities (ii) Borrowings (iii) Trade payables (iii) Other non-current liabilities (iv) Borrowings (iv) From it is in the specified in item (b) Provisions (c) Deferred tax liabilities (iv) Borrowings (iv) Trade payables (iv) Financial Liabilities (iv) Borrowings (iv) Trade payables (iv) Financial Liabilities (iv) Borrowings (iv) Trade payables (iv) Forrowings (iv) Trade payables (iv) Forrowings (iv) Trade payables (iv) Financial Liabilities (iv) Borrowings (iv) Trade payables (iv) Financial Liabilities				7	-
(i) Investments (ii) Trade receivables (iii) Loans (iv) Others (to be specified) (i) Deferred tax assets (net) (j) Other non-current assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade receivables (iii) Trade receivables (iii) Trade receivables (iii) Trade receivables (iv) Bank balances other than (iii) above (v) Loans (v) Loans (v) Unders (to be specified) (c) Current Tax Assets (Net) (d) Other current assets EQUITY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity LIABILITIES 1 Non-current liabilities (a) Financial Liabilities (ii) Borrowings (iii) Trade payables (iiii) Other financial liabilities (of Deferred tax liabilities (c) Deferred tax liabilities (d) Other non-current liabilities (e) Fronsisons (c) Deferred tax liabilities (ii) Borrowings (iii) Trade payables (iii) Other non-current liabilities (iv) Borrowings (iv) Trade payables (iv) Trade payables (iv) Borrowings (v) Deferred tax liabilities (v) Deforred tax liabilities (v) Deforrowings (v) Deforrowings (v) Deforred tax liabilities (v) Deforred tax liabilities (v) Deforred tax liabilities (v) Deforrowings (v) Deforred tax liabilities (v) Deforrowings (v) Deforred tax liabilities (v) Deforre				•	
(ii) Trade receivables 75.85 (iii) Loans 632.43 (iv) Others (to be specified) 34.58 (i) Deferred tax assets (net) 34.58 (j) Other non-current assets - 2 Current assets 127.64 (a) Investments - (ii) Investments - (ij) Investments 93.71 (iii) Cash and cash equivalents 7.47 (iv) Bank balances other than (iii) above - (v) Loans 36.55 (vi) Others (to be specified) - (c) Current Tax Assets (Net) - (d) Other current assets 16.71 EQUITY AND LIABILITIES Equity 1.075.04 (a) Equity Share capital 1,026.88 1,0 (b) Other Equity (178.54) (3 LIABILITIES 1 Non-current liabilities (i) Borrowings - - (ii) Other financial Liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (Net) - - (d) Other non-current liabilities - - (ii) Other financial Liabilities		Mark M. North Control of the Mark Mark			
(iii) Loans (iv) Others (to be specified) (i) Deferred tax assets (net) (j) Other non-current assets 2 Current assets (a) Inventories (b) Financial Assets (i) Investments (iii) Trade receivables (iiii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans (v) Loans (v) Loans (c) Current Tax Assets (Net) (d) Other current assets EQUITY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity LIABILITIES Non-current liabilities (i) Borrowings (iii) Trade payables (iiii) Other financial Liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities (i) Borrowings (ii) Trade payables (iii) Other non-current liabilities (a) Financial Liabilities (b) Provisions (c) Deferred tax liabilities (i) Borrowings (ii) Trade payables (iii) Other non-current liabilities (a) Financial Liabilities (a) Financial Liabilities (b) Provisions (c) Deferred tax liabilities (i) Borrowings (ii) Trade payables (iii) Other non-current liabilities (i) Borrowings (ii) Trade payables (iii) Trade payables		A STATE OF THE PROPERTY OF THE		75.05	75.85
(iv) Others (to be specified) (i) Deferred tax assets (net) 34.58 (j) Other non-current assets - 2 Current assets - (a) Inventories 127.64 (b) Financial Assets - (i) Investments - (ii) Trade receivables 93.71 (iii) Cash and cash equivalents 7.47 (iv) Bank balances other than (iii) above - (v) Loans 36.55 (vi) Others (to be specified) - (c) Current Tax Assets (Net) - (d) Other current assets 16.71 EQUITY AND LIABILITIES Equity 1.026.88 1,075.04 (a) Equity Share capital 1,026.88 1,0 (b) Other Equity (178.54) (1 LABILITIES (a) Financial Liabilities - (a) Financial Liabilities - - (i) Borrowings - - (ii) Trade payables - - (iii) Other financial liabilities - - (a) Equity financial Liabilities - - (b) Provisions - - (c		The state of the s			643.35
(i) Deferred tax assets (net) (j) Other non-current assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans (vi) Others (to be specified) (c) Current Tax Assets (Net) (d) Other current assets EQUITY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity (a) Financial Liabilities (a) Financial Liabilities (ii) Borrowings (iii) Trade payables (c) Deferred tax liabilities (a) Financial Liabilities (b) Other reduction than those specified in item (b) Provisions (c) Deferred tax liabilities (a) Financial Liabilities (b) Other reduction than those specified in item (c) Provisions (c) Deferred tax liabilities (d) Other non-current liabilities (ii) Borrowings (c) Deferred tax liabilities (iii) Trade payables				032.43	045.55
(j) Other non-current assets				24 50	34.58
2 Current assets (a) Inventories (b) Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans (v) Loans (vi) Others (to be specified) (c) Current Tax Assets (Net) (d) Other current assets EQUITY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity (c) Financial Liabilities (a) Financial Liabilities (ii) Borrowings (c) Deferred tax liabilities (Net) (d) Other non-current liabilities (a) Financial Liabilities (i) Deferred tax liabilities (i) Other non-current liabilities (i) Deferred tax liabilities (i) Other non-current liabilities (i) Provisions (c) Deferred tax liabilities (i) Borrowings (ii) Trade payables (iii) Trade payables				34.36	34.36
(a) Inventories (b) Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans (v) Loans (v) Others (to be specified) (c) Current Tax Assets (Net) (d) Other current assets EQUITY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity (a) Financial Liabilities (a) Financial Liabilities (i) Borrowings (iii) Trade payables (c) Deferred tax liabilities (a) Financial Liabilities (b) Other non-current liabilities (c) Deferred tax liabilities (d) Other non-current liabilities (e) Financial Liabilities (f) Borrowings (c) Deferred tax liabilities (g) Financial Liabilities (g) Fi	2			7	
(b) Financial Assets (i) Investments (ii) Trade receivables (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans (v) Others (to be specified) (c) Current Tax Assets (Net) (d) Other current assets EQUITY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity (a) Financial Liabilities (a) Financial Liabilities (ii) Borrowings (c) Deferred tax liabilities (Net) (d) Other non-current liabilities (a) Financial Liabilities (b) Other financial Liabilities (c) Deferred tax liabilities (d) Other non-current liabilities (e) Financial Liabilities (f) Borrowings (g) Financial Liabilities (g) Financial Lia	2	W. W.		127.64	
(i) Irrade receivables 93.71 (iii) Cash and cash equivalents 7.47 (iv) Bank balances other than (iii) above - 36.55 (v) Others (to be specified) - 6.00 (c) Current Tax Assets (Net) - 7.00 (d) Other current assets 16.71 EQUITY AND LIABILITIES Equity (7.00 (a) Equity Share capital 1.00 (b) Other Equity 1.00 (c) Financial Liabilities (7.00 (i) Trade payables (7.00 (ii) Trade payables (7.00 (iii) Other financial liabilities (7.00 (iv) Other financial liabilities (8.00 (iv) Other financial liabilities (9.00 (iv) Other financial liabilities (1.00 (iv) Other finan				127.04	
(iii) Trade receivables 93.71 (iii) Cash and cash equivalents 7.47 (iv) Bank balances other than (iii) above		March 12 - Committee of the Committee of		2.1	
(iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans (v) Loans (vi) Others (to be specified) (c) Current Tax Assets (Net) (d) Other current assets Total Assets 1,075.04 EQUITY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity LIABILITIES Non-current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables (iii) Other financial liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (a) Financial Liabilities (b) Other non-current liabilities (c) Deferred tax liabilities (d) Other non-current liabilities (i) Borrowings (ii) Trade payables (iii) Other Inancial Liabilities (2) Current liabilities (3) Financial Liabilities (4) Financial Liabilities (5) Borrowings (6) Deferred tax liabilities (6) Borrowings (7.47 (1.47		100 months 200 months (200 months)		93.71	5
(iv) Bank balances other than (iii) above (v) Loans (v) Others (to be specified) (c) Current Tax Assets (Net) (d) Other current assets Total Assets 10.71 EQUITY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity LIABILITIES Non-current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables (iii) Other financial liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (d) Other non-current liabilities (a) Financial Liabilities (b) Provisions (c) Deferred tax liabilities (d) Other non-current liabilities (i) Borrowings (ii) Trade payables (iii) Other liabilities (2) Current liabilities (3) Financial Liabilities (4) Financial Liabilities (5) Borrowings (6) Provisions (6) Provisions (7) Provisions (8) Provisions (9) Provisions (10) Other non-current liabilities (11) Trade payables (12) Provisions (13) Provisions (14) Other non-current liabilities (15) Borrowings (16) Provisions (17) Provisions (18) Provisions (19) Provisions (20) Provisions (21) Provisions (22) Provisions (36.55 (43) Provisions (44) Provisions (55) Provisions (66) Provisions (77) Provisions (78) Provisions (79) Provisions (79) Provisions (70) Provisions (70) Provisions (71) Provisions (71) Provisions (72) Provisions (73) Provisions (74) Provisions (75) Provisions (75) Provisions (76) Provisions (77) Provisions (77) Provisions (78) Provisions (79) Provisions (79) Provisions (79) Provisions (70) Provisions (70) Provisions (71) Provisions (71) Provisions (72) Provisions (73) Provisions (74) Provisions (75) Provisions (75) Provisions (76) Provisions (77) Provisions (77) Provisions (78) Provisions (79) Provis					2.18
(v) Loans (vi) Others (to be specified) (c) Current Tax Assets (Net) (d) Other current assets Total Assets EQUITY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity LIABILITIES Non-current liabilities (a) Financial Liabilities (ii) Borrowings (iii) Trade payables (c) Deferred tax liabilities (d) Other non-current liabilities (a) Financial Liabilities (id) Other non-current liabilities (id) Other non-current liabilities (id) Other non-current liabilities (id) Other non-current liabilities (if) Borrowings (if) Trade payables (if) Trade payables (if) Borrowings (if) Trade payables (if) Borrowings (if) Trade payables (if) Borrowings (if) Trade payables (if) Trade payables		Annual Annual Control of the Control		,.4,	2.10
(vi) Others (to be specified) (c) Current Tax Assets (Net) (d) Other current assets Total Assets EQUITY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity LIABILITIES Non-current liabilities (a) Financial Liabilities (i) Borrowings (iii) Other financial liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (d) Other non-current liabilities (d) Other non-current liabilities (a) Financial Liabilities (i) Borrowings (c) Deferred tax liabilities (i) Borrowings (ii) Trade payables 2 Current liabilities (i) Borrowings (ii) Trade payables				36.55	36.55
(c) Current Tax Assets (Net) (d) Other current assets Total Assets 1,075.04 8 EQUITY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity LIABILITIES Non-current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables (iii) Other financial liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities 2 Current liabilities (i) Borrowings (ii) Trade payables (iii) Trade payables (iii) Trade payables (iii) Trade payables (iii) Trade payables 2 Current liabilities (i) Borrowings (ii) Trade payables 2 223.42				50.55	30.55
(d) Other current assets Total Assets 1,075.04 8 EQUITY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity LIABILITIES Non-current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables (iii) Other financial liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (a) Financial Liabilities (c) Other non-current liabilities (c) Deferred tax liabilities (d) Other non-current liabilities (i) Borrowings (a) Financial Liabilities (i) Borrowings (ii) Trade payables (iii) Trade payables		•		<u>.</u>	20
EQUITY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity LIABILITIES Non-current liabilities (a) Financial Liabilities (ii) Borrowings (iii) Other financial liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (a) Financial Liabilities (ii) Other non-current liabilities (c) Deferred tax liabilities (d) Other non-current liabilities (ii) Borrowings (iii) Trade payables (iii) Trade payables 2 Current liabilities (i) Borrowings (ii) Trade payables 2 Current liabilities (i) Borrowings (ii) Trade payables		(2) (3) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4		16.71	-
EQUITY AND LIABILITIES Equity (a) Equity Share capital (b) Other Equity LIABILITIES Non-current liabilities (a) Financial Liabilities (ii) Trade payables (iii) Other financial liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (a) Financial Liabilities (a) Financial Liabilities (a) Financial Liabilities (a) Financial Liabilities (ii) Borrowings (ii) Trade payables (iii) Trade payables					845.82
(a) Equity Share capital (b) Other Equity LIABILITIES Non-current liabilities (a) Financial Liabilities (ii) Borrowings (iii) Other financial liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (d) Other non-current liabilities (a) Financial Liabilities (a) Financial Liabilities (ii) Borrowings (iii) Trade payables 2 Current liabilities (i) Borrowings (iii) Trade payables 1,026.88 (1,78.54) (178.54) (18.54) (19.54) (19.54) (19.54) (19.54) (19.54) (19.55) (19.55) (19.56)					
(b) Other Equity LIABILITIES Non-current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables (iii) Other financial liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Current liabilities (a) Financial Liabilities (ii) Borrowings (iii) Trade payables (178.54) (178.54) (178.54) (178.54)		1		1.026.88	1,026.88
LIABILITIES Non-current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables (iii) Other financial liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities 2 Current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables					(183.57)
Non-current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables (iii) Other financial liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables 7		No. 20		,,	,,
(i) Borrowings (ii) Trade payables (iii) Other financial liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables	1	Non-current liabilities			
(i) Borrowings (ii) Trade payables (iii) Other financial liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables					
(iii) Trade payables (iii) Other financial liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables (iii) Trade payables				_	-
(iii) Other financial liabilities (other than those specified in item (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables (other than those specified in item					
 (b) Provisions (c) Deferred tax liabilities (Net) (d) Other non-current liabilities Current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables 					
(c) Deferred tax liabilities (Net) (d) Other non-current liabilities Current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables					
(d) Other non-current liabilities Current liabilities (α) Financial Liabilities (i) Borrowings (ii) Trade payables 223.42				2	
2 Current liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables 223.42					
(i) Borrowings - (ii) Trade payables 223.42	2				
(ii) Trade payables 223.42		(α) Financial Liabilities			
(ii) Trade payables 223.42		(i) Borrowings		-	-
		With the second		223.42	1.07
TO A CONTROL OF THE C					
(b) Other current liabilities 1.19				1.19	1.44
(c) Provisions 2.08		Annal Andrews Comment Comment Comment Comment			
(d) Current Tax Liabilities (Net)				-	-
				1.075.04	845.82

For Pharmaids Pharmaceuticals to an all

Place: Hyderabad Date: 05/02/2021

.Padmaja Kalyani

Office Address: 503, Amrutha Estate, Himayath Nagar, Hyderabad - 500 Ph: 045 40122151

CIN No: L52520TG1989LC009679, GSTIN No: 36AABCP46

Email: pharmaids125@gmail.com, Web: www.pharmaids.com



Pharmaids Pharmaceuticals Limited

Pharmaids Pharmaceuticals Limited

Statement of Cash Flows for the Nine month ended 31st December 2020

Rs. (In Lakhs)

			Rs. (In Lakhs)
		Figures as at	Figures as at
	Section 2 Section 2	the end of	the end of
	Particulars	31.12.2020	31.12.2019
		(Unaudited)	(Audited)
	•	(onducted)	(Machine)
Α	CASHFLOW FROM OPERATIING ACTIVITES:		
	Net Profit before Tax	7.11	(33.9
	Adjustment for:		
	Depreciation and Amortization	3.36	2.7
	Interest Charged		0.
	Interest Income	-	-
	Dividend Income/Gain on sale of Investments		-
	Provision / write off for doubtful trade receivables	-	-
	Deferred Tax	-	-
	Operating Profit before change in working capital	10.47	(31.1
	Madda and days		
	Working capital changes: Changes in Inventories	(127.64)	
	Changes in Trade Receviables	(93.71)	13.
	Change in Short term loans and advances	(0.10)	33
-	Changes in Trade payables	222.36	(15.9
_	Changes in Other liabilities	(0.25)	(3.5
	Changes in Other Habilities Changes in Provisions	(0.23)	13.
_	Changes in Other Current Assets	(16.71)	
	Cash generated from Operations	(5.58)	(4.3
	Direct tax paid (Net of Refunds)	/E E01	(0.3
	Net Cash inflow from Operating Activities (A)	(5.58)	(4.0
В	CASH FLOW FROM INVESTING ACTIVITIES:		
	Proceeds from Sale Asset		-
	Government assistance	-	
	Interest received		
	Dividend Income /Gain on Sale of Investments received	-	-
	Purchase of property, plant & equipments, intangible assets and		
	Capital Advance	(0.15)	(3.
	Investment in Associate		-
	Intangible assets under development		-
	Long term loans and Advances Given/(Repaid)	11.01	(1.
	Net Cash inflow from Investing Activities (B)	10.86	(5.
С	CASH FLOW FROM FINANCING ACTIVITIES:		
_	Proceeds from borrowings	0.00	-
	Net increase/ (decrease) in working capital demand loans		12
	Payment of lease liabilities	-	-
	Increase in Restricted Bank Balances other than Cash & Cash		
_	Equivalents Dividends paid (including distribution tax)		-
	printerias para (including distribution tax)		
	Interest and other finance costs (including borrowing cost capitalised)	-	(0.
	Net Cash inflow from Financing Activities (C)	0.00	(0.
1	Net (decrease)/increase in cash and cash equivalents (A+B+C)	5.28	(9.
11	a) Cash and Cash Equivalents at the beginning of the year	2.19	10.
	b) Effect of Exchange difference on restatement of foreign currency		
	cash and cash equivalents		
	c) Effect of Fairvalue change of investment held for Trading		
Ш	Cash and Cash Equivalents at the end of the year (I+II)	7.47	1.
IV	Cash and Cash Equivalents at the end of the year		
	Balances with Banks	2.69	1
	Cash on Hand	4.77	0

Place: Hyderabad Date: 05/02/2021 For Pharmaids Pharmaceuticals Limite

Office Address: 503, Amrutha Estate, Himayath Nagar, Hyderabad - 500029. Ph: 048

CIN No: L52520TG1989LC009679, GSTIN No: 36AABCP4657N2ZW Email: pharmaids125@gmail.com, Web: www.pharmaids.com





INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

To
The Board of Directors,
Pharmaids Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited Financial Results of PHARMAIDS PHARMACEUTICALS LIMITED ("the Company") for the Quarter/ Nine Months Ended 31st December, 2020 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed necessary procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Scheme of Amalgamation of Emergent Bio Naturals Limited (EBNL) with Pharmaids Pharmaceuticals Limited was approved by the National Company Law Tribunal vide its order dated 27th September, 2019. The certified copy of the NCLT order was filed with Registered of Companies on 12th October, 2019 consequently the Scheme became operative, and effective date is 1st April, 2018 (Appointed Date). The Company has accounted the Amalgamation as per Appendix C of IND AS 103 Business Combination, the financial information in respect of prior periods has been restated as if the business combination had occurred on April 1st, 2018.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The Previously issued financial information of the Company for the quarter ended and Nine months ended 31st December, 2019 included in the Statement, have been restated to give effect to the Scheme of Amalgamation ("the Scheme") of Pharmaids Pharmaceuticals Limited (PPL) with Emergent Bio Naturals Limited, as explained in note 5 to the Statement.

The adjustments made to the previously issued financial information to give effect to the Scheme have been reviewed by us. Our report is not modified in respect of this matter.

Place : Hyderabad

Date: 05th February, 2021

UDIN: 21231499AAAAAW4152

For PPKG & CO Chartered Accountants FRN No. 009655S



SWETHA TOSHNIWAL (Partner) M. No. 231499